BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 12170449)

  • 21. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
    Nabholtz JM
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):7-13. PubMed ID: 10426453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of gemcitabine in the treatment of advanced and metastatic breast cancer.
    Heinemann V
    Oncology; 2003; 64(3):191-206. PubMed ID: 12697958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant therapy of breast cancer with docetaxel-containing combination (TAC).
    Boér K; Láng I; Juhos E; Pintér T; Szántó J
    Pathol Oncol Res; 2003; 9(3):166-9. PubMed ID: 14530809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Optimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer].
    Fattoruso SI; Rossi S; Vici P; Di Filippo F; Botti C; Di Lauro L; Foggi P; Saracca E; Ferranti FR; Visca P; Lopez M
    Clin Ter; 2008; 159(6):443-7. PubMed ID: 19169606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
    Nabholtz JM; Mackey JR; Smylie M; Paterson A; Noël DR; Al-Tweigeri T; Tonkin K; North S; Azli N; Riva A
    J Clin Oncol; 2001 Jan; 19(2):314-21. PubMed ID: 11208821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.
    Di Leo A; Crown J; Nogaret JM; Duffy K; Bartholomeus S; Dolci S; Rowan S; O'Higgins N; Paesmans M; Larsimont D; Riva A; Piccart MJ
    Ann Oncol; 2000 Feb; 11(2):169-75. PubMed ID: 10761751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
    Nagykálnai T
    Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction between Herceptin and taxanes.
    Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
    Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
    Sparano JA
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospects with docetaxel in the treatment of patients with breast cancer.
    Marty M; Extra JM; Cottu PH; Espié M
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S26-9. PubMed ID: 9486101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
    von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
    J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
    Pegram MD; O'Callaghan C
    Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S15-9. PubMed ID: 11970740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer.
    Nabholtz JM; Mackey J; Smylie M; Tonkin K
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):27-31. PubMed ID: 9865709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The choice of adjuvant combination therapies with taxanes: rationale and issues addressed in ongoing studies.
    Nabholtz JM; Riva A
    Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S7-14. PubMed ID: 11970739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy.
    Crown J; Pegram M
    Breast Cancer Res Treat; 2003; 79 Suppl 1():S11-8. PubMed ID: 12868801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in the use of taxanes in the adjuvant therapy of breast cancer.
    Nabholtz JM; Vannetzel JM; Llory JF; Bouffette P
    Clin Breast Cancer; 2003 Aug; 4(3):187-92. PubMed ID: 14499011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
    Perez EA; Geeraerts L; Suman VJ; Adjei AA; Baron AT; Hatfield AK; Maihle N; Michalak JC; Kuross SA; Kugler JW; Lafky JM; Ingle JN
    Ann Oncol; 2002 Aug; 13(8):1225-35. PubMed ID: 12181246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase III randomized trials of docetaxel in patients with metastatic breast cancer.
    Crown J
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):33-8. PubMed ID: 10403472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel in combination chemotherapy for metastatic breast cancer.
    Khayat D; Antoine E
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.